Table 2 Drug candidates determined based on patient subset analysis.
CMAP compound name | p.val | adj.p.val |
|---|---|---|
(A) NEUROD6-elevating compounds | ||
sodium phenylbutyrate | 8.03E-05 | 4.23E-02 |
arachidonic acid | 8.22E-05 | 4.23E-02 |
2-deoxy-D-glucose | 8.59E-05 | 4.23E-02 |
fasudil | 8.76E-05 | 4.23E-02 |
nordihydroguaiaretic acid | 1.04E-04 | 4.23E-02 |
monastrol | 1.09E-04 | 4.23E-02 |
tacrolimus | 1.12E-04 | 4.23E-02 |
quercetin | 1.12E-04 | 4.23E-02 |
sulindac | 1.14E-04 | 4.23E-02 |
troglitazone | 1.17E-04 | 4.23E-02 |
staurosporine | 1.17E-04 | 4.23E-02 |
troglitazone | 1.22E-04 | 4.23E-02 |
thalidomide | 1.26E-04 | 4.23E-02 |
CP-944629 | 1.35E-04 | 4.23E-02 |
mercaptopurine | 1.40E-04 | 4.23E-02 |
haloperidol | 1.49E-04 | 4.23E-02 |
exisulind | 1.57E-04 | 4.23E-02 |
sirolimus | 1.71E-04 | 4.23E-02 |
tanespimycin | 1.71E-04 | 4.23E-02 |
suramin sodium | 1.74E-04 | 4.23E-02 |
genistein | 1.76E-04 | 4.23E-02 |
erastin | 1.78E-04 | 4.23E-02 |
clofibrate | 1.80E-04 | 4.23E-02 |
LY-294002 | 1.92E-04 | 4.23E-02 |
tanespimycin | 1.93E-04 | 4.23E-02 |
LY-294002 | 1.97E-04 | 4.23E-02 |
prednisolone | 1.99E-04 | 4.23E-02 |
fulvestrant | 2.01E-04 | 4.23E-02 |
meteneprost | 2.05E-04 | 4.23E-02 |
monorden | 2.17E-04 | 4.23E-02 |
tretinoin | 2.22E-04 | 4.23E-02 |
nifedipine | 2.30E-04 | 4.23E-02 |
sulindac sulfide | 2.32E-04 | 4.23E-02 |
wortmannin | 2.36E-04 | 4.23E-02 |
MK-886 | 2.46E-04 | 4.29E-02 |
PF-01378883-00 | 2.59E-04 | 4.38E-02 |
monorden | 2.82E-04 | 4.65E-02 |
iloprost | 3.06E-04 | 4.91E-02 |
Note: 34 unique compounds. Repeats due to differing cell lines or repeated experiments. | ||
(B) SNAP25-elevating compounds | ||
valproic acid | 2.20E-05 | 1.91E-02 |
guanabenz | 9.14E-05 | 3.81E-02 |
karakoline | 8.89E-05 | 3.81E-02 |
tetracycline | 1.03E-04 | 4.01E-02 |
diloxanide | 1.28E-04 | 4.45E-02 |
metoprolol | 1.38E-04 | 4.52E-02 |
yohimbic acid | 1.59E-04 | 4.75E-02 |
azapropazone | 1.63E-04 | 4.75E-02 |
proguanil | 1.93E-04 | 4.92E-02 |
